Leukemia

白血病

• 批准号: 8606540
• 负责人: A. THOMAS LOOK
• 金额: $ 11.45万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-12-01 至 2016-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8606540
• 关键词: Acute leukemia; Animal Model; Cancer Center; Cancer Center Support Grant; Cancer Etiology; Cells; Cessation of life; Clinic; Clinical Trials; Dana-Farber Cancer Institute; Disease; Dysmyelopoietic Syndromes; Experimental Leukemia; Funding; Goals; Institution; Instruction; Laboratories; Laboratory Research; Malignant Neoplasms; Molecular; Myeloproliferative disease; Outcome; Pathogenesis; Pathway interactions; Patients; Peer Review; Phase; Phenotype; Preclinical Testing; Proteins; Publications; Research Personnel; Time; Translating; Translations; United States; cost; design; improved; innovation; leukemia; member; novel; programs

The DF/HCC Leukemia Program continues to focus on advancing the understanding of molecular pathogenesis as a means to define novel pathways and protein targets that can be inhibited to improve the outcome of patients with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms. The long-range goal of the Program is to accelerate the translation of novel discoveries from the laboratory to the clinic, first into preclinical testing in animal models and then into innovative, investigator-initiated Phase I or 11 clinical trials. The Program's Specific Aims are: 1) to identify novel cellular and molecular mechanisms that contribute to the pathogenesis of leukemia and related diseases; 2) to generate accurate animal models of leukemia to improve the understanding of pathogenesis and to develop targeted anti-leukemic agents; and 3) to design and implement clinical trials to translate laboratory research discoveries made within the Leukemia Program and the Cancer Center as a whole. The Leukemia Program has been CCSG funded since 2000. The Program received an outstanding merit score at the time of the last competitive review in 2005. The 60 Program members represent four departments of HMS, one department of HSPH and six DF/HCC member institutions. The Program continues to be well-funded with $35.6 million in peer-reviewed funding, of which $16 million was from the NCI and $19.6 million was other peer reviewed funding (2009, total costs). Program members had 879 in Program-relevant publications from 2006 through 2010. Of these 16% were intra-programmatic interactions, 43% were inter-programmatic and 27% were inter-institutional.

DF/HCC 白血病项目继续致力于增进对分子生物学的理解 发病机制作为定义新途径和蛋白质靶点的手段，可以通过抑制这些途径和蛋白质靶点来改善 急性白血病、骨髓增生异常综合征和骨髓增生性肿瘤患者的结果。这 该计划的长期目标是加速将新发现从实验室转化为现实 临床，首先在动物模型中进行临床前测试，然后进入研究者发起的创新 I 期或 11 期 临床试验。该计划的具体目标是：1）确定新的细胞和分子机制 促进白血病及相关疾病的发病机制； 2）建立准确的动物模型 提高对白血病发病机制的了解并开发靶向抗白血病药物；和 3) 设计和实施临床试验，以转化白血病领域的实验室研究发现 计划和整个癌症中心。 自 2000 年以来，白血病项目一直由 CCSG 资助。该项目获得了出色的成绩 截至 2005 年最后一次竞争性审查时。60 名计划成员代表了四个部门 HMS、HSPH 的一个部门和 6 个 DF/HCC 成员机构。该计划继续 资金充足，同行评审资金达 3560 万美元，其中 1600 万美元来自 NCI，19.6 美元来自 万元是其他同行评审资金（2009 年，总费用）。计划成员在计划相关领域有 879 名 2006 年至 2010 年的出版物。其中 16% 是程序内交互，43% 是 跨项目，27% 是跨机构。